DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 482 participants.

Also called NCT03334630

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 482 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03334630
Other papers using this trial's data
  • A Novel Temperature-Controlled Radiofrequency Catheter Ablation System Used to Treat Patients With Paroxysmal Atrial Fibrillation JACC. Clinical electrophysiology, 2021-03 DOI, PubMed 33516712

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, France, Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03334630. Randomized; single masking; primary purpose treatment. Start 2017-11-06 (actual); primary completion 2019-11-18 (actual). Results posted on 2020-12-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation
Acronym
DIAMOND-AF
Condition
Paroxysmal Atrial Fibrillation
Condition
Atrial Fibrillation
Intervention (Device)
DiamondTemp Ablation catheter
Intervention (Device)
TactiCath Quartz Ablation catheter
Lead sponsor
Medtronic Cardiac Ablation Solutions (class: industry)

Record details

Record id
cardio:ct-nct03334630
Content hash
e7371b53cb59011718c4ee173f0596525d44e37ba6c3d91f30f2681de0598652